STAGE IIIA BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts bladder cancer treatment in major trial
Disease control OngoingThis Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Bladder cancer survivors share how treatment changes their daily lives
Knowledge-focused OngoingThis study follows 204 people with bladder cancer to see how their quality of life changes after treatment like surgery or radiation. Participants fill out surveys about physical function, pain, fatigue, anxiety, and bladder, bowel, and sexual health. The goal is to understand ho…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC